Eli Lilly and Company (LLY) Stake Raised by Buckingham Asset Management LLC
Buckingham Asset Management LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 21.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,232 shares of the company’s stock after buying an additional 568 shares during the quarter. Buckingham Asset Management LLC’s holdings in Eli Lilly and were worth $266,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently bought and sold shares of LLY. Waldron LP grew its holdings in shares of Eli Lilly and by 46.7% during the first quarter. Waldron LP now owns 4,948 shares of the company’s stock valued at $415,000 after buying an additional 1,574 shares during the last quarter. Handelsbanken Fonder AB lifted its position in Eli Lilly and by 8.1% during the first quarter. Handelsbanken Fonder AB now owns 267,940 shares of the company’s stock valued at $22,536,000 after purchasing an additional 20,000 shares during the period. Pictet Asset Management Ltd. lifted its position in Eli Lilly and by 2.3% during the first quarter. Pictet Asset Management Ltd. now owns 898,344 shares of the company’s stock valued at $75,560,000 after purchasing an additional 19,996 shares during the period. MUFG Americas Holdings Corp lifted its position in Eli Lilly and by 11.7% during the first quarter. MUFG Americas Holdings Corp now owns 128,819 shares of the company’s stock valued at $10,835,000 after purchasing an additional 13,537 shares during the period. Finally, LS Investment Advisors LLC lifted its position in Eli Lilly and by 14.5% during the first quarter. LS Investment Advisors LLC now owns 34,621 shares of the company’s stock valued at $2,912,000 after purchasing an additional 4,374 shares during the period. Hedge funds and other institutional investors own 75.53% of the company’s stock.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last ninety days, insiders have sold 990,000 shares of company stock valued at $82,949,650. 0.20% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Eli Lilly and Company (LLY) Stake Raised by Buckingham Asset Management LLC” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/10/22/eli-lilly-and-company-lly-stake-raised-by-buckingham-asset-management-llc.html.
Shares of Eli Lilly and Company (LLY) opened at 87.23 on Friday. The company has a market cap of $92.03 billion, a price-to-earnings ratio of 37.75 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $89.09. The stock has a 50 day moving average of $84.38 and a 200 day moving average of $82.29.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.86 earnings per share. Equities research analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.38%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.
A number of research analysts recently weighed in on LLY shares. Barclays PLC increased their price objective on shares of Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Tuesday, July 4th. Citigroup Inc. restated a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a research report on Tuesday, July 4th. Zacks Investment Research upgraded shares of Eli Lilly and from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Jefferies Group LLC restated a “buy” rating and set a $96.00 price objective (up previously from $93.00) on shares of Eli Lilly and in a research report on Thursday, July 13th. Finally, Deutsche Bank AG restated a “buy” rating and set a $91.00 price objective (up previously from $90.00) on shares of Eli Lilly and in a research report on Monday, July 17th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $88.97.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.